Wolters Kluwers Nv (WOSB)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 87.90 |
|---|---|
| 52-week range | 54.74 – 114.80 |
| Return, 1 month / 3 months | +30.0% / +48.0% |
| Return, 1 year / 3 years | −18.9% / −22.3% |
| Trend | Uptrend |
| RSI (14) | 84 |
| Volatility (1 year) | 39.1% |
| Worst drawdown (1 year) | -49.1% |
| Average daily value traded | 0.28M EUR |
| Dividend yield | 3.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Wolters Kluwer is an information services company based in the Netherlands. It supplies software, digital content and expert tools to professionals in law, tax, accounting, healthcare, finance and compliance. Its products help lawyers, tax advisers, clinicians and risk managers find reliable information and complete complex work. Customers include law firms, hospitals, banks, insurers and government bodies, mainly in Europe and North America, with operations in many other countries around the world.
The shares are listed on the XETRA Stock Exchange in Germany under the code WOSB, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Wolters Kluwers Nv (WOSB) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 87.90 on 23 October 2026.
Its price-based Market X-Ray is 57 out of 100 (a fair price profile), ranking 297 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 18.9% and over the last three months it rose 48.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 74 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 33.6% | ||
| From 52-week high | -22.9% | ||
| Momentum | 67 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 48.0% | ||
| 6-month return | 38.0% | ||
| 12-month return, skipping the last month | -37.6% | ||
| Stability (higher is calmer) | 30 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 39.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -49.1% | ||
| Liquidity | 58 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.28M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 54 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 3.0% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +7.4% |
|---|---|
| 1 month | +30.0% |
| 3 months | +48.0% |
| 6 months | +38.0% |
| 1 year | −18.9% |
| 3 years | −22.3% |
| 5 years | – |
Signals
| 50-day / 200-day average | 71.59 / 65.81 |
|---|---|
| Golden / death cross (60 days) | Golden, 24 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.00 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 Sep 2026 | EUR 1.0100 |
| 25 May 2026 | EUR 1.5900 |
| 26 Aug 2025 | EUR 0.9300 |
| 19 May 2025 | EUR 1.5000 |
| 27 Aug 2024 | EUR 0.8300 |
| 10 May 2024 | EUR 1.3600 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.